ADC Contract Manufacturing Market, 2018-2030: The Capabilities of Contract Services Providers

News provided by

Oct 19, 2018, 17:15 ET

DUBLIN, Oct. 19, 2018 /PRNewswire/ --

The "ADC Contract Manufacturing Market (3rd Edition), 2018-2030" report has been added to ResearchAndMarkets.com's offering.

The ADC Contract Manufacturing Market (3rd edition), 2018-2030 report offers a comprehensive study of the current scenario and future potential of the contract manufacturing market for ADCs. The study features an in-depth analysis, highlighting the capabilities of contract services providers engaged in this domain.

In addition to other elements, the study includes:

An overview of the current status of the market with respect to the players involved in the manufacturing of ADCs. It features information on headquarters, size of the company, the types of services offered (antibody manufacturing / HPAPI or cytotoxic manufacturing / linker manufacturing / conjugation / fill-finish), location of manufacturing facilities, year of establishment of company / organization, scale of operations, and additional development services offered for ADCs (proof-of-concept studies / process development and scale-up / anaytical development).
Elaborate profiles of the contract service providers that are either one-stop-shops (offering services from antibody manufacturing to fill/ finish operations) or offer conjugation services at the commercial scale. Each profile provides a brief overview of the company, its financial information, details on ADC manufacturing capabilities, location of facilities, recent developments, and a comprehensive future outlook.
A comparative analysis of the key contract manufacturers based onvarious parameters, including company size, year of establishment, number of ADC manufacturing services offered, annual revenues, scale of operation, number of ADC development services offered and number of facilities for conjugation services.
An analysis of the recent investments (since 2012) made in this domain, the proceeds of which were intended to be used for the expansion or establishment of new facilities dedicated to offering ADC related services.
An analysis of the recent collaborations (since 2012) focused on manufacturing of ADCs on the basis of year in which the agreement was signed, type of agreement, key players and the geographical distribution of this activity.
An estimate of the overall ADC manufacturing / bioconjugation capacity (in grams / batch) of contract service providers based on information provided on their respective websites (wherever available) and additional data collated via secondary and primary research. The analysis highlights the distribution of global capacity by size of the company / organization (small-sized, mid-sized and large-sized) and geography (North America, Europe and Asia Pacific).
An overview of the ADCs that are already approved and those that are under development (clinical and preclinical), featuring information related to their current phase of development (wherever applicable), key target indications, developer company / organization, affiliated technology provider(s) and the type(s) of cytotoxin(s) and linker(s) used.
A review of the evolution of ADC conjugation technologies, highlighting the various types pf approaches that have been adopted in the past, and the different generations of linkers. It also highlights the competition between contemporary technology platforms.
A comprehensive geographical clinical trial analysis of completed, ongoing and planned studies of various ADCs (approved / under development). It provides details related to the different types of payloads and linkers investigated / being investigated across various geographies, based on the number of trials registered, current trial status, phase of development, number of patients enrolled and duration of the (recently initiated) trials (2015 onwards).
An informed estimate of the annual demand for ADC products (in grams), taking into account commercial, as well as clinical scale requirements, based on parameters such as target patient population, dosing frequency and dose strength of approved products and clinical stage candidates.
A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, featuring a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall ADC contract manufacturing market.

One of the key objectives of this report was to evaluate the current opportunity and the future potential of the ADC contract manufacturing market over the coming decade. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2018-2030.

In addition, we have provided the likely distribution of the market based on scale of operation (commercial, phase III, phase II and phase I), component / process type (antibody manufacturing, HPAPI / cytotoxic production, conjugation / linker and fill / finish), target indications (solid tumors and hematological malignancies), type of payload used (auristatin, calicheamicin (ozogamicin), duocarmycin, DXd (exatecan derivative), maytansinoid, pyrrolobenzodiazepines (talirine, tesirine) and others), type of linker used (succinimidyl 4-(n-maleimidomethyl) cyclohexane-1-carboxylate, valine-citrulline, hydrazone, valine-alanine, n-succinimidyl-4-(2-pyridyldithio) butanoate and others) and geography (North America, Europe, Asia Pacific and rest of the world).

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Our opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain.

The report features detailed transcripts of interviews held with following stakeholders:

Aldo Braca (Chief Executive Officer, BSP Pharmaceuticals) and Giorgio Salciarini (Technical Business Development Manager, BSP Pharmaceuticals)
Anthony DeBoer (Director, Business Development, Synaffix)
Christian Bailly (Director of CDMO, Pierre Fabre)
Christian Rohlff (Chief Executive Officer & Founder, Oxford BioTherapeutics)
Jennifer L. Mitcham (Director, Business Development, Catalent Pharma Solutions) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions)
John Burt (Chief Executive Officer, Abzena)
Laurent Ducry (Head of Bioconjugates Commercial Development, Lonza)
Mark Wright (Site Head, Piramal Healthcare)
Sasha Koniev (Chief Executive Officer & Co-Founder, Syndivia)
Anonymous (Director, Business Development, Leading CMO)
Anonymous (Chief Executive Officer, Leading CMO)

Key Topics Covered:

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Essential Components of ADCs
3.3. ADC Manufacturing
3.4. Challenges Associated with Supply Chain and Method Transfer
3.5. Selecting a CMO Partner

4. ADC CONTRACT MANUFACTURERS: CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. ADC Contract Manufacturers: Overall Market Landscape
4.3. Antibody Manufacturing Service Providers
4.4. HPAPI / Cytotoxic Drug Manufacturing Service Providers

5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Abzena
5.3. Ajinomoto Althea
5.4. BSP Pharmaceuticals
5.5. CARBOGEN AMCIS
5.6. Catalent Pharma Solutions
5.7. Cerbios-Pharma
5.8. Creative Biolabs
5.9. Goodwin Biotechnology
5.10. Levena Biopharma
5.11. Lonza
5.12. MabPlex
5.13. Merck (SAFC)
5.14. Novasep
5.15. Pierre Fabre
5.16. Piramal Pharma Solutions
5.17. Syngene
5.18. WuXi Biologics

6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.3. Affiliated Insights

7. ADC CONTRACT MANUFACTURERS: FACILITY EXPANSIONS
7.1. Chapter Overview
7.2. ADC Contract Manufacturers: Recent Facility Expansions

8. ADC CONTRACT MANUFACTURERS: RECENT PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. ADC Contract Manufacturers: List of Partnerships and Collaborations

9. ADC MANUFACTURING: CAPACITY ANALYSIS
9.1. Chapter Overview
9.2. Key Assumptions and Methodology
9.3. ADC Manufacturing: Overall Installed Global Capacity

10. ADC THERAPEUTICS: MARKET OVERVIEW
10.1. Chapter Overview
10.2. ADC Therapeutics: Clinical Pipeline
10.3. ADC Therapeutics: Preclinical / Discovery Pipeline

11. ADC CONJUGATION TECHNOLOGY PLATFORMS
11.1. Chapter Overview
11.2. First Generation ADC Technologies
11.3. Second Generation ADC Technologies
11.4. Third Generation ADC Technologies
11.5. Evolutionary Analysis

12. GEOGRAPHICAL CLINICAL TRIALS ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. ADC Therapeutics: Overall Clinical Trial Analysis
12.4. ADC Therapeutics: Clinical Trial Analysis by Payload Type
12.5. ADC Therapeutics: Clinical Trial Analysis by Linker Type

13. ADC THERAPEUTICS: DEMAND ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. ADC Therapeutics: Overall Annual Demand

14. MARKET SIZING AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Forecast Methodology
14.3. Overall ADC Therapeutics Market, 2018-2030
14.4. Input Data and Key Assumptions
14.5. Overall ADC Contract Manufacturing Market, 2018-2030
14.6. ADC Contract Manufacturing Market for Commercial Products, 2018-2030
14.7. ADC Contract Manufacturing Market for Clinical Products, 2018-2030

15. SWOT ANALYSIS
15.1. Chapter Overview

16. CONCLUSION
16.1. Given the Growing Pipeline of ADC Therapeutics and Associated Manufacturing Challenges, Outsourcing is Considered to be a Viable Business Strategy in this Domain
16.2. Current Market Landscape is Relatively Niche with a Limited Number of Companies Offering End-To-End Services and a Few Players Providing Services at Commercial Scale
16.3. To Keep Pace with the Growing Demand for ADC Therapeutics, Many Contract Manufacturers Have Made Investments or Entered Into Strategic Alliances to Expand Existing Capabilities
16.4. Several Clinical Trials are being Conducted to Evaluate ADC Therapeutics Worldwide, the Majority of Such Studies being Centered in the US
16.5. Owing to the Presence of Several Small Companies and Start-Ups, the Trend of Outsourcing Such Operations is Likely to Flourish in the Coming Years
16.6. As More Late Stage Candidates Receive Approvals, the Annual Demand for ADC Therapeutics is Anticipated to Increase

17. INTERVIEW TRANSCRIPTS

18. APPENDIX 1: TABULATED DATA

19. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

3P Biopharmaceuticals
AB Sciex
AbbVie
AbGenomics
ABL Bio
Abzena
ACES Pharma
Adar Biotech
ADC Biotechnology
ADC Therapeutics
Advanced BioScience Laboratories
Aesica Pharmaceuticals
Affinity Life Sciences
Agensys
Agno Pharma
Ajinomoto Althea
Alcami
Aldevron
Alkermes
Allozyne
Almac
Alpha Cancer Technologies
Alphora Research
Alteogen
Amatsigroup
Ambrx
Amgen
AMPAC Fine Chemicals
AMRI
Angiex
Anogen
APO-T
Aptuit
AqueaTether Therapeutics
Arabio
Arch Pharmalabs
Asana BioSciences
Ash Stevens
Aspyrian Therapeutics
Astellas Pharma
AstraZeneca
Asymchem
AURA Biotechnologies
AutekBio
Avanthera
Avid Bioservices
Batavia Biosciences
Baxter BioPharma Solutions
Bayer HealthCare
BerGenBio
Bharat Serums and Vaccines
BIBITEC
BINEX
Bio-Synthesis
BioAgilytix
BioConnection
Biomatik
BioMed Valley Discoveries
Biosynergy
BioTechLogic
BioTechnique
Biotechpharma
Biotecnol
Biotest
BioVectra
Biovian
BlinkBio
Bliss Biopharmaceutical
Boehringer Ingelheim BioXcellence
Bristol-Myers Squibb
Bryllan
BSP Pharmaceuticals
Cambrex
Cambridge Major Laboratories
Capsugel
CARBOGEN AMCIS
Catalent Pharma Solutions
Cedarburg Pharmaceuticals
Celgene
Cell Culture Company
Cell Essentials
Cellerant Therapeutics
CellMosaic
Celltrion
Celon Laboratories
Celonic
Centrose
Cerbios-Pharma
Charles River Laboratories
ChemCon
ChemPartner
ChemSun Pharmaceutical
Chiome Bioscience
Chugai Pharmaceutical
CinnaGen
CMC Biologics
Cobra Biologics
Coldstream Laboratories
Compugen
Concortis Biotherapeutics
Cook Pharmica
CordenPharma
Creative Biolabs
Crystal Pharma
Custom Pharma Services
CytomX Therapeutics
Cytovance Biologics
Daiichi Sankyo
Dalton Pharma Services
Debiopharm
DM Bio
Dorizoe Lifesciences
Dottikon Exclusive Synthesis
DSM Pharmaceuticals
EirGen Pharma
EirGenix
Eli Lilly
Emergent BioSolutions
Esperance Pharmaceuticals
ETH Zurich
EuBiologics
Evonik
Excella
Farmabios
FineTech Pharmaceuticals
Formation Biologics
Formex
Formosa Laboratories
Fortis Therapeutics
ForRobin
FOSUN Pharma
FUJIFILM Diosynth Biotechnologies
Fusion Antibodies
Gala Biotech
GE Healthcare
GEA Pharma Systems
Genentech
Genmab
Genzyme
Glenmark Pharmaceuticals
Glycotope Biotechnology
Glythera
Goodwin Biotechnology
GP Pharm
Grand River Aseptic Manufacturing
Green Cross
Groningen Research Institute of Pharmacy
GSK
GTP Technology
HALIX
Halozyme
Hangzhou DAC Biotech
Haupt Pharma
Heidelberg Pharma
Helsinn Advanced Synthesis
Heraeus Deutschland
Hetero
Hong Kong Institute of Biotechnology
Hospira One2One
ICROM
Idifarma
IDT Australia
IDT Biologika
Igenica Biotherapeutics
ImmunoGen
Immunomedics
Indena
Innate Pharma
Inno Biologics
Innovation Center for Immune Therapy, Tsinghua University
Intas Pharmaceuticals
Integrity Bio
Intellect Neurosciences
IRIX Pharmaceuticals
JHL Biotech
Johns Hopkins University
Johnson Matthey
Kamat Pharmatech
KBI Biopharma
Kemwell Biopharma
Kyongbo Pharmaceutical
Kyowa Hakko Kirin
Labochim
Laboratorios Normon
LAMPIRE Biological Laboratories
LegoChem Biosciences
Leica Biosystems
Levena Biopharma
LFB Biomanufacturing
LinXis
Lonza
MAB Discovery
MabPlex
MabVax Therapeutics
MacroGenics
Maine Biotechnology Services
MassBiologics
Medichem
MedImmune
Meditope Biosciences
Medix Biochemica
Menarini Group
Merck (SAFC)
Meridian Life Science
Merrimack Pharmaceuticals
Mersana Therapeutics
Metrics Contract Services
Millennium Pharmaceuticals
MINAKEM High Potent
Mitsubishi Tanabe Pharma
Molecular and Cellular Therapeutics, University of Minnesota
Morphotek
MuseChem
Mycenax Biotech
NanoValent Pharmaceuticals
National Cancer Institute
National Research Council Canada
NBE Therapeutics
NerPharma
Nitto Avecia Pharma Services
Nordic Nanovector
Nova Laboratories
Novartis
Novasep
OBI Pharma
OctoPlus
Olon
OmniChem
Oncotec Pharma Produktion
OsoBio
Oxford BioTherapeutics
Panacea Biotec
Paragon Bioservices
Particle Sciences
Patheon
Penn Pharma
Pfanstiehl
Pfizer
Pharmaceutics International
PharmaMar
Pharmatek
Pharmedartis
Philochem
Philogen
Pierre Fabre
Piramal Pharma Solutions
Polymun Scientific
PrasFarma
Praxis Pharmaceutical
Precision Antibody
PREMAS Biotech
ProBioGen
Procos
ProJect Pharmaceutics
ProMab Biotechnologies
PX'Therapeutics
Quotient Sciences
Recipharm
Redwood Bioscience
Regeneron Pharmaceuticals
Regis Technologies
Reliance Life Sciences
RemeGen
Rentschler Biopharma
Research Corporation Technologies
Richter-Helm BioLogics
Roche
Rottendorf Pharma
Saltigo
Samsung Medical Center
Sandoz
Sanofi
Sartorius Stedim Biotech
ScinoPharm
Seasun Biomaterials
Seattle Genetics
Shenogen
Siegfried
Sorrento Therapeutics
Spirogen
STA Pharmaceutical
Stason Pharmaceuticals
Stemcentrx
Sutro Biopharma
Symbiosis Pharmaceutical Services
Symphogen
Synaffix
Syndivia
Syngene
Syntagon
Synthon
Synthorx
Takara Bio
Takeda Oncology
TAPI
TBD-Biodiscovery
Telix Pharmaceuticals
The Chemistry Research Solution
The Scripps Research Institute
Theranyx
Therapure Biopharma
Thermo Fisher Scientific
Toyobo Biologics
Transporin
TranXenoGen
Triphase Accelerator
Tube Pharma
Uman Pharma
University of Bonn
University of California
University of Georgia
UPM Pharmaceuticals
Uquifa
Vaccinex
Vetter Pharma
Vista Biologicals
Visterra
VUAB Pharma
Waisman Biomanufacturing
Weill Cornell Medicine
Wolfe Laboratories
WuXi Biologics
Xintela
Yale School of Medicine
Zymeworks

For more information about this report visit https://www.researchandmarkets.com/research/5xfc6w/adc_contract?w=5

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets